⏳ Fetching live dividend data...
Home › Calculator › EDIT Dividend Calculator 2026
Editas Medicine, Inc. · NASDAQ
Price: $2.65 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in EDIT → $64963568708.83M in 10 years · $5,406,648,018,699,816.00/month
Editas Medicine, Inc. is a leading biotechnology firm focused on clinical-stage genome editing, with a primary mission to pioneer groundbreaking genetic therapies designed to address a wide array of severe medical conditions. The company leverages a unique, in-house developed gene editing platform that utilizes cutting-edge CRISPR technology. Editas's pipeline features several promising candidates, including EDIT-101, which is currently undergoing Phase 1/2 clinical trials for Leber Congenital Amaurosis 10, a genetic disorder causing inherited childhood blindness. Additionally, EDIT-102 is under development to tackle Usher Syndrome 2A, a form of retinitis pigmentosa accompanied by hearing impairment, as well as autosomal dominant retinitis pigmentosa, a progressive retinal degeneration. Its portfolio also includes EDIT-301, designed to treat sickle cell disease and transfusion-dependent beta-thalassemia. Furthermore, Editas is advancing gene-edited Natural Killer (NK) cell therapies for solid tumor cancers, alpha-beta T cell therapies for various malignancies, and gamma delta T cell treatments, also targeting cancer. An early-stage research initiative is also underway to discover a therapeutic solution for a neurological disorder. The company has forged strategic partnerships to broaden its research and development capabilities. These include a collaboration with Juno Therapeutics, Inc. for engineered T cells in oncology; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited focused on discovering, developing, and marketing gene-edited treatments for a range of eye conditions; and research collaborations with Asklepios BioPharmaceutical, Inc. (also referred to as AskBio) to develop therapies for neurological diseases. Originally established as Gengine, Inc., the company rebranded to Editas Medicine, Inc. in November 2013, the same year it was incorporated. Its operations are based in Cambridge, Massachusetts.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open EDIT position with:
Real after-tax yield depends on where you live and how you hold EDIT.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 75.61% | 72.81% | $7,561 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 64.27% | 61.47% | $6,427 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 60.49% | 57.69% | $6,049 / yr |
| 🇬🇧 UK ISA | 0% | 75.61% | 72.81% | $7,561 / yr |
| 🇬🇧 UK Taxable | 8.75% | 68.99% | 66.19% | $6,899 / yr |
| 🇨🇦 TFSA | 0% | 75.61% | 72.81% | $7,561 / yr |
| 🇨🇦 CA Taxable | 25% | 56.71% | 53.91% | $5,671 / yr |
| 🇦🇺 Super (pension) | 15% | 64.27% | 61.47% | $6,427 / yr |
| 🇦🇺 AU Taxable | 30% | 52.93% | 50.13% | $5,293 / yr |
| 🇩🇪 DE Taxable | 26.375% | 55.67% | 52.87% | $5,567 / yr |
| 🇫🇷 FR Taxable | 30% | 52.93% | 50.13% | $5,293 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
EDIT pays quarterly — 4 times per year. Next ex-div: TBD.
How EDIT compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for EDIT sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-06-03 | 464 | $2.70 | $1.3K | ||
| Sale | 2026-06-03 | 15,380 | $2.70 | $41.5K | ||
| Sale | 2026-06-03 | 731 | $2.70 | $2.0K | ||
| A-Award | 2026-03-12 | 1,015,200 | $2.54 | $2.58M | ||
| A-Award | 2026-03-12 | 292,856 | $2.54 | $743.9K | ||
| A-Award | 2026-03-12 | 292,856 | $2.54 | $743.9K | ||
| Sale | 2026-03-03 | 5,394 | $2.02 | $10.9K | ||
| Sale | 2026-03-03 | 474 | $2.02 | $957.00 | ||
| Sale | 2026-03-03 | 749 | $2.02 | $1.5K | ||
| Sale | 2025-12-03 | 713 | $2.15 | $1.5K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the EDIT dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →